Author

Amal S. Kolt

Observed name: Amal Kolt

OpenAlex ID: A5017419085

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

2023 · Joshua Bennett, Chiharu Ishikawa, et al. · Blood · 56

Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia

2024 · Scott B. Hoyt, Chris J. Finocchio, et al. · ACS Medicinal Chemistry Letters · 11

IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia

2025 · Scott B. Hoyt, Chris J. Finocchio, et al. · ACS Medicinal Chemistry Letters · 6

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

2023 · Jan S. Rosenbaum, Amal S. Kolt, et al. · Blood · 5

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

2022 · Jan S Rosenbaum, Scott B. Hoyt, et al. · Blood · 3

Works count: 5

Citation count: 81

H-index: 4

I10-index: 2